Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence

World Journal of Gastroenterology

Volumn 21, Issue 28, 2015, Pages 8516-8526

  García, María Luisa Gutiérrez ^a   Blasco Algora, Sara ^a   Fernández Rodríguez, Conrado M ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Alcohol abstinence; Alcohol dependence; Alcohol use disorders; Alcohol withdrawal syndrome; Alcoholic liver disease

Indexed keywords

ACAMPROSATE; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; DISULFIRAM; ETIRACETAM; GABAPENTIN; NALMEFENE; NALTREXONE; ONDANSETRON; THIAMINE; TOPIRAMATE; DRUGS USED IN THE TREATMENT OF ADDICTION;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOLISM; BEHAVIOR CHANGE; DETOXIFICATION; DRUG THERAPY; FOLLOW UP; HUMAN; META ANALYSIS (TOPIC); NUTRITIONAL SUPPORT; OFF LABEL DRUG USE; PARENTERAL NUTRITION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; COMPLICATION; DRINKING BEHAVIOR; LIVER DISEASES, ALCOHOLIC; MULTIMODALITY CANCER THERAPY; PREDICTIVE VALUE; PREVENTION AND CONTROL; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; LIVER DISEASES, ALCOHOLIC; PREDICTIVE VALUE OF TESTS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84937826683     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i28.8516     Document Type: Review

References (105)

1. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005; 352: 596-607 [PMID: 15703424]
2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373: 2223-2233 [PMID: 19560604 DOI: 10.1016/S0140-6736(09)60746-7]
3. World Health Organization. European Status Report on Alcohol and Health 2010. Available from: URL: http://www.euro.who.int/--data/assets/pdf-file/0004/128065/e94533.pdf
4. Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis 2014; 11: E109 [PMID: 24967831 DOI: 10.5888/pcd11.130293]
5. th ed (DSM-5). Arlington, VA: American Psychiatric Association, 2013
6. Corrao G, Bagnardi V, Zambon A, Torchio P. Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol Alcohol 1998; 33: 381-392 [PMID: 9719397]
7. Zatoński WA, Sulkowska U, Mańczuk M, Rehm J, Boffetta P, Lowenfels AB, La Vecchia C. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16: 193-201 [PMID: 20606444 DOI: 10.1159/000317248]
8. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006; 367: 52-56 [PMID: 16399153]
9. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, Valla DC. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 45-53 [PMID: 12640727]
10. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372: 1619-1628 [PMID: 25901427 DOI: 10.1056/NEJMoa1412278]
11. Anderson P, Chisholm D, Fuhr DC. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 2009; 373: 2234-2246 [PMID: 19560605 DOI: 10.1016/S0140-6736(09)60744-3]
12. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J; U.S. Preventive Services Task Force. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140: 557-568 [PMID: 15068985]
13. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]
14. U.S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 2004; 140: 554-556 [PMID: 15068984]
15. Canagasaby A, Vinson DC. Screening for hazardous or harmful drinking using one or two quantity-frequency questions. Alcohol Alcohol 2005; 40: 208-213 [PMID: 15797883]
16. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med 2010; 170: 1155-1160 [PMID: 20625025 DOI: 10.1001/archinternmed.2010.140]
17. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med 2009; 24: 783-788 [PMID: 19247718 DOI: 10.1007/s11606-009-0928-6]
18. Fiellin DA, Reid MC, O'Connor PG. Screening for alcohol problems in primary care: a systematic review. Arch Intern Med 2000; 160: 1977-1989 [PMID: 10888972]
19. Moyer VA; Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med 2013; 159: 210-218 [PMID: 23698791 DOI: 10.7326/0003-4819-159-3-201308060-00652]
20. Taj N, Devera-Sales A, Vinson DC. Screening for problem drinking: does a single question work? J Fam Pract 1998; 46: 328-335 [PMID: 9564375]
21. Vinson DC, Kruse RL, Seale JP. Simplifying alcohol assessment: two questions to identify alcohol use disorders. Alcohol Clin Exp Res 2007; 31: 1392-1398 [PMID: 17559544]
22. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984; 252: 1905-1907 [PMID: 6471323]
23. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974; 131: 1121-1123 [PMID: 4416585]
24. Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 1971; 127: 1653-1658 [PMID: 5565851]
25. Storgaard H, Nielsen SD, Gluud C. The validity of the Michigan Alcoholism Screening Test (MAST). Alcohol Alcohol 1994; 29: 493-502 [PMID: 7811333]
26. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993; 88: 791-804 [PMID: 8329970]
27. Bradley KA, Bush KR, Epler AJ, Dobie DJ, Davis TM, Sporleder JL, Maynard C, Burman ML, Kivlahan DR. Two brief alcohol-screening tests From the Alcohol Use Disorders Identification Test (AUDIT): validation in a female Veterans Affairs patient population. Arch Intern Med 2003; 163: 821-829 [PMID: 12695273]
28. Williams R, Vinson DC. Validation of a single screening question for problem drinking. J Fam Pract 2001; 50: 307-312 [PMID: 11300981]
29. Friedmann PD, Saitz R, Gogineni A, Zhang JX, Stein MD. Validation of the screening strategy in the NIAAA "Physicians' Guide to Helping Patients with Alcohol Problems". J Stud Alcohol 2001; 62: 234-238 [PMID: 11332444]
30. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31: 1208-1217 [PMID: 17451397]
31. Rubinsky AD, Dawson DA, Williams EC, Kivlahan DR, Bradley KA. AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers. Alcohol Clin Exp Res 2013; 37: 1380-1390 [PMID: 23906469 DOI: 10.1111/acer.12092]
32. Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction 2002; 97: 279-292 [PMID: 11964101]
33. Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction 1993; 88: 315-335 [PMID: 8461850]
34. nd ed. New York: Guilford Press, 2002
35. Rollnick S, Heather N, Gold R, Hall W. Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 1992; 87: 743-754 [PMID: 1591525]
36. Collins SE, Logan DE, Neighbors C. Which came first: the readiness or the change? Longitudinal relationships between readiness to change and drinking among college drinkers. Addiction 2010; 105: 1899-1909 [PMID: 20854333 DOI: 10.1111/j.1360-0443.2010.03064.x]
37. Gavin DR, Sobell LC, Sobell MB. Evaluation of the readiness to change questionnaire with problem drinkers in treatment. J Subst Abuse 1998; 10: 53-58 [PMID: 9720006]
38. Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N. The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev 2009; 28: 301-323 [PMID: 19489992 DOI: 10.1111/j.1465-3362.2009.00071.x]
39. Emmen MJ, Schippers GM, Bleijenberg G, Wollersheim H. Effectiveness of opportunistic brief interventions for problem drinking in a general hospital setting: systematic review. BMJ 2004; 328: 318 [PMID: 14729657]
40. Beich A, Thorsen T, Rollnick S. Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis. BMJ 2003; 327: 536-542 [PMID: 12958114]
41. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-1795 [PMID: 12724485]
42. Santavy P. Multidisciplinary approach to a Marfan syndrome patient with emphasis on cardiovascular complications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157: 1-4 [PMID: 23567654 DOI: 10.5507/bp.2013.023]
43. Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, Jara G, Kasser C, Melbourne J; Working Group on the Management of Alcohol Withdrawal Delirium, Practice Guidelines Committee, American Society of Addiction Medicine. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 2004; 164: 1405-1412 [PMID: 15249349]
44. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353-1357 [PMID: 2597811]
45. Pittman B, Gueorguieva R, Krupitsky E, Rudenko AA, Flannery BA, Krystal JH. Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcohol Clin Exp Res 2007; 31: 612-618 [PMID: 17374040]
46. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 1999; 160: 649-655 [PMID: 10101999]
47. th ed. New York: McGraw-Hill, 2011: 629-647
48. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; (3): CD005063 [PMID: 20238336 DOI: 10.1002/14651858.CD005063. pub3]
49. Hughes DW, Vanwert E, Lepori L, Adams BD. Propofol for benzodiazepine-refractory alcohol withdrawal in a non-mechanically ventilated patient. Am J Emerg Med 2014; 32: 112.e3-112.e4 [PMID: 24075805 DOI: 10.1016/j.ajem.2013.08.044]
50. Coomes TR, Smith SW. Successful use of propofol in refractory delirium tremens. Ann Emerg Med 1997; 30: 825-828 [PMID: 9398785]
51. Lorentzen K, Lauritsen AØ, Bendtsen AO. Use of propofol infusion in alcohol withdrawal-induced refractory delirium tremens. Dan Med J 2014; 61: A4807 [PMID: 24814732]
52. Barrons R, Roberts N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther 2010; 35: 153-167 [PMID: 20456734 DOI: 10.1111/j.1365-2710.2009.01098.x]
53. Lucht M, Kuehn KU, Armbruster J, Abraham G, Gaensicke M, Barnow S, Tretzel H, Freyberger HJ. Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcohol 2003; 38: 168-175 [PMID: 12634266]
54. Hillbom M, Tokola R, Kuusela V, Kärkkäinen P, Källi-Lemma L, Pilke A, Kaste M. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 1989; 6: 223-226 [PMID: 2500138]
55. Polycarpou A, Papanikolaou P, Ioannidis JP, Contopoulos-Ioannidis DG. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2005; (3): CD005064 [PMID: 16034965]
56. Addolorato G, Leggio L, Abenavoli L, Caputo F, Gasbarrini G. Baclofen for outpatient treatment of alcohol withdrawal syndrome. J Fam Pract 2005; 54: 24 [PMID: 15623403]
57. Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2015; 4: CD008502 [PMID: 25836263 DOI: 10.1002/14651858.CD008502.pub4]
58. Prater CD, Miller KE, Zylstra RG. Outpatient detoxification of the addicted or alcoholic patient. Am Fam Physician 1999; 60: 1175-1183 [PMID: 10507746]
59. Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007; 31: 604-611 [PMID: 17374039]
60. Thomson AD, Cook CC, Touquet R, Henry JA; Royal College of Physicians, London. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department. Alcohol Alcohol 2002; 37: 513-521 [PMID: 12414541]
61. Rees E, Gowing LR. Supplementary thiamine is still important in alcohol dependence. Alcohol Alcohol 2013; 48: 88-92 [PMID: 23161892 DOI: 10.1093/alcalc/ags120]
62. Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin Liver Dis 2012; 16: 805-826 [PMID: 23101983 DOI: 10.1016/j.cld.2012.08.009]
63. Teixeira J, Mota T, Fernandes JC. Nutritional evaluation of alcoholic inpatients admitted for alcohol detoxification. Alcohol Alcohol 2011; 46: 558-560 [PMID: 21632576 DOI: 10.1093/alcalc/agr062]
64. Cook CC, Hallwood PM, Thomson AD. B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Alcohol Alcohol 1998; 33: 317-336 [PMID: 9719389]
65. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318-1325 [PMID: 10208148]
66. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 2012; 17: 513-527 [PMID: 22458728 DOI: 10.1111/j.1369-1600.2012.00454.x]
67. Testino G, Leone S, Borro P. Treatment of alcohol dependence: recent progress and reduction of consumption. Minerva Med 2014; 105: 447-466 [PMID: 25392958]
68. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013; 108: 275-293 [PMID: 23075288 DOI: 10.1111/j.1360-0443.2012.04054.x]
69. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811-828 [PMID: 15200577]
70. Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311: 1889-1900 [PMID: 24825644 DOI: 10.1001/jama.2014.3628]
71. Niederhofer H, Staffen W. Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev 2003; 22: 295-297 [PMID: 15385223]
72. Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann Intern Med 1979; 90: 901-904 [PMID: 389121]
73. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256: 1449-1455 [PMID: 3528541]
74. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26: 290-302 [PMID: 16702894]
75. Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011; 35: 1749-1758 [PMID: 21615426 DOI: 10.1111/j.1530-0277.2011.01523.x]
76. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734-1739 [PMID: 11742047]
77. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; (12): CD001867 [PMID: 21154349 DOI: 10.1002/14651858.CD001867]
78. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A functional polymorphism of the muopioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552 [PMID: 12813472]
79. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-1625 [PMID: 15811981]
80. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008; 32: 1105-1110 [PMID: 18540918 DOI: 10.1111/j.1530-0277.2008.00690.x]
81. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; (9): CD004332 [PMID: 20824837 DOI: 10.1002/14651858.CD004332]
82. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012; 36: 497-508 [PMID: 21895717 DOI: 10.1111/j.1530-0277.2011.01616.x]
83. Higuchi S. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). J Clin Psychiatry 2015; 76: 181-188 [PMID: 25742205 DOI: 10.4088/JCP.13m08940]
84. Soyka M. Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol 2014; 17: 675-684 [PMID: 24246244 DOI: 10.1017/S1461145713001284]
85. Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23: 1432-1442 [PMID: 23562264 DOI: 10.1016/j.euroneuro.2013.02.006]
86. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013; 73: 706-713 [PMID: 23237314 DOI: 10.1016/j.biopsych.2012.10.020]
87. Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, Mäkelä R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007; 31: 1179-1187 [PMID: 17451401]
88. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017 [PMID: 16670409]
89. Müller CA, Geisel O, Banas R, Heinz A. Current pharmacological treatment approaches for alcohol dependence. Expert Opin Pharmacother 2014; 15: 471-481 [PMID: 24456374 DOI: 10.1517/14656566.2014.876008]
90. Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, Heinz A, Förg A, Volkmar K, Glauner T, Schaefer M. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol 2012; 32: 558-562 [PMID: 22722516 DOI: 10.1097/JCP.0b013e31825e213e]
91. Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, A Tompkins D, Stout R. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res 2012; 36: 1421-1430 [PMID: 22324516 DOI: 10.1111/j.1530-0277.2011.01716.x]
92. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-1685 [PMID: 12767733]
93. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-1651 [PMID: 17925516]
94. Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103: 2035-2044 [PMID: 18855810 DOI: 10.1111/j.1360-0443.2008.02355.x]
95. Rubio G, Martínez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 2009; 29: 584-589 [PMID: 19910725 DOI: 10.1097/JCP.0b013e3181bfdb79]
96. Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 2014; 38: 1481-1488 [PMID: 24796492 DOI: 10.1111/acer.12411]
97. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1691-1700 [PMID: 18052562]
98. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2014; 174: 70-77 [PMID: 24190578 DOI: 10.1001/jamainternmed.2013.11950]
99. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-508 [PMID: 12217947]
100. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-1922 [PMID: 18068515]
101. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34: 1849-1857 [PMID: 20662805 DOI: 10.1111/j.1530-0277.2010.01273.x]
102. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R; Baclofen Study Group. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011; 46: 312-317 [PMID: 21414953 DOI: 10.1093/alcalc/agr017]
103. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284: 963-971 [PMID: 10944641]
104. Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011; 168: 265-275 [PMID: 21247998 DOI: 10.1176/appi.ajp.2010.10050755]
105. Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud N, Li MD. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry 2013; 170: 1020-1031 [PMID: 23897038 DOI: 10.1176/appi.ajp.2013.12091163]